78 completed, 10 terminated, 10 unknown, 8 recruiting. 27 Phase 3, 26 Phase 2, 21 Phase 4, 19 Not applicable, 11 Phase 1.
Follow Medroxyprogesterone Acetate: new trials by email Literature Review of Medroxyprogesterone Acetate trials Research Report on Medroxyprogesterone Acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins - Endometrial Cancer, Endometrial Cancer Stage I | Phase 4 | Not yet recruiting | Hospital Universitari de Bellvitge | 80 | 2027-01-01 | 2026-06-10 |
| Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS) Ganirelix ; Cetrorelix, Medroxyprogesterone Acetate ; Micronized Progesterone, Linzagolix - Infertility, Female, Ovulation Induction | Not applicable | Not yet recruiting | Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) | 120 | 2026-09-01 | 2026-09-30 |
| Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer medroxyprogesterone acetate tablets OR megestrol acetate, Cisplatin, Carboplatin + Paclitaxel - Endometrial Cancer, Uterine Neoplasms | Phase 3 | Recruiting | University College, London | 600 | 2026-06-29 | 2026-09-21 |
| Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification PD1 antibody, Medroxyprogesterone Acetate 500 MG, Megestrol Acetate 160 MG - Endometrial Cancer, Fertility | Phase 2 / Phase 3 | Recruiting | Fudan University | 260 | 2026-01-25 | 2026-03-13 |
| Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months BAY865028, Medroxyprogesterone acetate - Endometrial Hyperplasia | Phase 3 | Withdrawn | Bayer | 2025-11-24 | 2026-07-30 | |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study Depo Medroxyprogesterone acetate - Postpartum Contraception, Depot Medroxyprogesterone Acetate | Phase 4 | Completed | University of California, San Diego | 40 | 2025-03-26 | 2025-09-10 |
| Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A. Ganirelix, Medroxyprogesterone Acetate 10 MG - Stimulation in the Ovary, Embryo | Phase 4 | Unknown | Ginefiv | 144 | 2024-10-15 | 2024-10-15 |
| PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA) - Endometrial Cancer, Endometrioid Carcinoma | Not applicable | Recruiting | Peking University People's Hospital | 10 | 2024-09-02 | 2026-08-10 |
| Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Relugolix, Relugolix placebo - Heavy Menstrual Bleeding, Uterine Fibroids | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 120 | 2024-01-15 | 2026-02-02 |
| Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery Dienogest, Depo Medroxyprogesterone acetate, Leuprolide (as Leuprolide Acetate) - Endometriosis Ovary | Phase 3 | Completed | Universitas Diponegoro | 80 | 2023-09-04 | 2024-12-11 |
| Endometrial Biopsy in Progestin Contraceptive Users DMPA, Etonogestrel implant - Contraception | Early Phase 1 | Completed | Oregon Health and Science University | 59 | 2023-07-01 | 2026-10-14 |
| Evaluation of Efficacy and Safety of Topical 1% Medroxyprogesterone in the Corneal Epithelium Healing After PRK prepared drop of medroxy progestrone acetat 1% - Photorefractive Keratectomy | Phase 2 / Phase 3 | Completed | Isfahan University of Medical Sciences | 74 | 2023-04-21 | 2023-08-02 |
| Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles Gonadotropin releasing hormone antagonist (Cetrotide), Medroxyprogesterone Acetate (Tarlusal), Dydrogesterone - Infertility | Not applicable | Completed | Bezmialem Vakif University | 297 | 2023-03-15 | 2024-10-15 |
| Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer Provera - Endometrium Cancer | Phase 4 | Completed | University of British Columbia | 96 | 2023-03-15 | 2026-04-13 |
| Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia Medroxyprogesterone acetate + Atorvastatin - Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I | Phase 2 | Unknown | Peking University People's Hospital | 82 | 2023-01-06 | 2024-07-11 |
| Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients Medroxyprogesterone Acetate 500 MG Oral Tablet, Levonorgestrel-Releasing Intrauterine System - Fertility Sparing | Phase 2 / Phase 3 | Unknown | Hua Li | 148 | 2022-11-01 | 2022-10-04 |
| Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients Depot-Medroxyprogestereone Acetate - Contraception | Phase 4 | Completed | Northwestern University | 263 | 2022-08-01 | 2026-10-15 |
| Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation MedroxyPROGESTERone Injection [Depo-Provera], Other - Arteriovenous Malformations | Phase 4 | Unknown | HaEmek Medical Center, Israel | 28 | 2022-08-01 | 2022-08-08 |
| Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer Megestrol Acetate 160 MG Oral Tablet, Medroxyprogesterone Acetate 500 MG, Triprorelin Acetate - Endometrial Neoplasm Malignant Stage I | Phase 2 | Recruiting | Fudan University | 104 | 2022-03-11 | 2026-06-04 |
Showing 20 of 111. Sign in to see all of them.
Endometrial Neoplasms (12) · Infertility (7) · Endometrial Hyperplasia (6) · Menorrhagia (6) · Acquired Immunodeficiency Syndrome (5) · HIV Infections (4) · Metrorrhagia (4) · Polycystic Ovary Syndrome (4) · Anovulation (2) · Breast Feeding (2) · Cardiovascular Diseases (2) · Endometriosis (2) · Heart Diseases (2) · Neoplasms (2) · Obesity (2)
FHI 360 (4) · Bayer (3) · University of Washington (3) · Assiut University (2) · Eli Lilly and Company (2) · Emory University (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Fudan University (2) · Kaiser Permanente (2) · Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Peking University People's Hospital (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · University of British Columbia (2)
United States (55) · China (9) · Canada (8) · Dominican Republic (6) · Brazil (5) · Chile (4) · Argentina (3) · Egypt (3) · Spain (3) · Thailand (3) · Turkey (Türkiye) (3) · Finland (2) · France (2) · Malawi (2) · Mexico (2)
Vera Halpern, MD (3) · Carolyn Westhoff, MD, MSc (2) · Lisa Haddad, MD (2) · Albert Asante, MD, MPH (1) · Alicia Smith, PhD (1) · Aline Talhouk, PhD (1) · Alireza Peyman, MD (1) · Alison Edelman, MD (1) · Amneris E Luque, M.D. (1) · Angela R Dempsey, MD, MPH (1) · Anita L. Nelson, M.D. (1) · Anitra Beasley, MD (1)
PMID 17494097, PMID 32909630, PMID 10954759, PMID 15784709, PMID 15968009, PMID 16757526, PMID 16940442, PMID 17012455, PMID 17303493, PMID 18174456, PMID 18226670, PMID 19155011, PMID 19489872, PMID 19963436, PMID 20580029, PMID 20733445, PMID 21078629, PMID 21475963, PMID 21619701, PMID 22780885, PMID 22959906, PMID 22981957, PMID 23635731, PMID 24028749, PMID 24286192, PMID 24438370, PMID 24656555, PMID 25481376, PMID 25624326, PMID 29746813, PMID 30222141, PMID 30927417, PMID 31131846, PMID 31374188, PMID 31752969, PMID 32533883, PMID 32819394, PMID 33485608, PMID 33706343, PMID 33814126, PMID 34709526, PMID 35102226, PMID 35128365, PMID 35483431, PMID 36576860, PMID 36622252
U54HD042454 (2), 2023 (1), K01TW009657 (1), K12HD001271 (1), K23HD078153 (1), R01HD072663 (1), R01HD095741 (1), R01HL070081 (1), R01MH083782 (1), U01AI068636 (1), U01AR042540 (1), U10CA027469 (1), U10CA180868 (1), U48DP001944 (1), UL1TR001082 (1)